Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
KAVANAGH SARAH B reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Sarah B. Kavanagh received an equity grant tied to her board service. She was awarded 45,871 common shares in the form of restricted share units (RSUs) with a grant date value of $250,000, at no cash cost to her.
The RSUs vest on the date immediately preceding the company’s next Annual Meeting of Shareholders and will be settled in common shares. Following this award, Kavanagh directly holds 282,230 common shares, reflecting routine, compensation-related stock-based pay for a non-employee director rather than an open-market purchase or sale.
GOETTLER MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Michael Goettler received an equity compensation grant in the form of 45,871 restricted share units (RSUs) with a stated grant date value of $250,000. These RSUs vest immediately before the company’s next Annual Meeting of Shareholders and will be settled in common shares, increasing his direct holdings to 76,020 shares.
Garcia Christian A reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. director Christian A. Garcia received an award of 45,871 common shares on May 22, 2026, reported as restricted share units granted to non-employee directors. The RSUs have a grant-date value of $250,000 and vest immediately before the company’s next Annual Meeting of Shareholders.
After this equity award, Garcia directly holds 135,578 common shares. The RSUs will be settled in Bausch Health common shares when they vest, increasing his share ownership if he continues to serve through the vesting date.
Bausch Health Companies Inc. director Frank D. Lee reported an open-market sale of common shares. On May 19, 2026, he sold 24,456 common shares at an average price of $5.43 per share. Following this transaction, he directly holds 49,339 common shares.
According to the footnote, the shares were sold in the open market under a Rule 10b5-1 trading plan to fund estimated tax obligations from a previously vested equity award granted to the company’s non-employee directors. The filing shows no derivative positions remaining in this report.
Bausch Health Companies Inc. disclosed a new insider filing for director Eiry Roberts on a Form 3. This form establishes her status as a reporting person for the company’s securities. The filing does not list any stock or option transactions or provide current holdings.
Bausch Health Companies Inc. reported results of its Annual Meeting of Shareholders held on May 19, 2026. Shareholders elected all nominated directors, including new director Eiry W. Roberts, M.D., to serve until the 2027 annual meeting or earlier resignation or removal.
Shareholders also approved, on a non-binding advisory basis, the compensation of the Named Executive Officers as described in the company’s proxy materials. In addition, they appointed PricewaterhouseCoopers LLP as the independent registered public accounting firm through the 2027 annual meeting and authorized the board to set the auditors’ remuneration.
Bausch Health Companies Inc. reports first-quarter 2026 results showing a sharp swing to loss driven by a major goodwill write-down. Revenue reached $2,524 million, up from $2,259 million a year earlier, but operating performance was overshadowed by non-cash charges.
The company recorded a $1,426 million goodwill impairment in its Salix reporting unit after Phase 3 trial failures, leading to a net loss of $1,431 million versus a $86 million loss in 2025. Shareholders’ equity moved from positive $377 million at year-end 2025 to a deficit of $1,082 million, while long-term debt remained high at $20,212 million principal.
Bausch Health Companies Inc. reported strong Q1 2026 revenue growth but a large accounting loss driven by a goodwill charge. Consolidated revenue was $2.52 billion, up 12% year over year and 7% on an organic basis, led by 18% organic growth at Salix and 6% organic growth at Bausch + Lomb.
GAAP net loss attributable to Bausch Health was $1.423 billion, mainly from a $1.426 billion goodwill impairment tied to the Salix RED‑C program. On a non‑GAAP basis, adjusted net income attributable to Bausch Health rose to $296 million, with adjusted EPS of $0.78 versus $0.59 a year earlier and adjusted EBITDA attributable to Bausch Health of $837 million, up from $661 million.
The company generated $230 million of operating cash in the quarter and ended March 31, 2026 with $1.299 billion in cash and cash equivalents and $20.764 billion of total long‑term debt and other. Management reaffirmed 2026 guidance, targeting consolidated revenue of $10.67–$10.92 billion and adjusted EBITDA of $3.885–$4.010 billion, and highlighted ongoing Phase 3 development of larsucosterol for alcohol‑associated hepatitis.